Complete Guide to Ruc Pharmacokinetics
Overview
Ruc is a PARP inhibitor used in the Oncology therapeutic area. It is indicated for BRCA-mutant and HRD+ breast cancer. Semi-mechanistic PK/PD model for rucaparib (PARP inhibitor) with DDR-based tumor growth inhibition. Two-compartment clinical PK with Gompertz TGI model showing synthetic lethality in BRCA-mutant and HRD+ tumors. Based on Villette et al. (2025) Br J Cancer.
Mechanism of Action
Ruc exerts its pharmacological effect by targeting PARP (poly ADP-ribose polymerase). As a PARP inhibitor, it modulates this target to achieve therapeutic efficacy in BRCA-mutant and HRD+ breast cancer. Understanding the target engagement is critical for interpreting the pharmacokinetic-pharmacodynamic (PK/PD) relationship and optimizing dosing regimens.
Key Pharmacokinetic Parameters
The following parameters are derived from published Semi-mechanistic PK/PD models for Ruc:
| Parameter | Value |
|---|---|
| CL F | clinical PK (2-compartment oral) |
| t half | ~17 h |
| PD model | Gompertz tumor growth inhibition with DDR-based synthetic lethality |
| covariates | HR deficiency status, BRCA mutation, body weight |
Parameters represent typical population estimates from published literature. Individual values may vary.
Dosing & Administration
Ruc is administered via the Oral route. Oral administration involves absorption from the gastrointestinal tract, and bioavailability may be affected by food intake, formulation, and first-pass metabolism.
Dosing recommendations should always follow approved prescribing information. The interactive simulator allows you to explore different dosing scenarios and their impact on drug exposure metrics such as AUC, Cmax, and Ctrough.
Clinical Considerations
In the Oncology therapeutic area, for the treatment of BRCA-mutant and HRD+ breast cancer, understanding the pharmacokinetics of Ruc is essential for dose optimization and therapeutic drug monitoring. Key clinical factors that may affect Ruc pharmacokinetics include:
- •Body weight and body composition
- •Renal and hepatic function
- •Drug-drug interactions and concomitant medications
- •Age, sex, and genetic polymorphisms
Interactive Ruc PK Simulator
Explore Ruc pharmacokinetics interactively. Adjust doses, dosing intervals, and patient covariates to visualize concentration-time profiles in real time.
Frequently Asked Questions
What is the half-life of Ruc?
The elimination half-life of Ruc depends on patient-specific factors. Based on published models, the typical half-life is approximately ~17 h.
How is Ruc administered?
Ruc is administered via the Oral route. It is indicated for BRCA-mutant and HRD+ breast cancer. As a PARP inhibitor, dosing regimens should follow approved prescribing information and clinical guidelines.
What are the key PK parameters of Ruc?
Key pharmacokinetic parameters for Ruc include clearance (CL), volume of distribution (Vd), and elimination half-life. See the PK Parameters section above for specific values from published models.
Can I simulate Ruc dosing scenarios for free?
Yes! PKPDBuilder offers a completely free, interactive Ruc PK simulator based on published pharmacometric models. No login required. Use it to explore different doses, dosing intervals, and patient covariates.
⚠️ Disclaimer
This guide is for research and educational purposes only. It is not intended for clinical decision-making or patient dosing. Parameters are derived from published literature and represent population estimates. Always consult approved prescribing information for clinical use.